I 

118TH CONGRESS 

1ST SESSION H. R. 6243 

To direct the Secretary of Labor to issue an occupational safety and health 

standard that requires employers to keep opioid overdose reversal drugs 

onsite and develop and implement training plans to respond to drug 

overdose emergencies and to amend the Omnibus Crime Control and 

Safe Streets Act of 1968 to expand the grants authorized under the 

Comprehensive Opioid Abuse Grant Program. 

IN THE HOUSE OF REPRESENTATIVES 

NOVEMBER 6, 2023 

Mr. GALLEGO (for himself and Mr. NUNN of Iowa) introduced the following 

bill; which was referred to the Committee on Education and the Workforce, and in addition to the Committee on the Judiciary, for a period 

to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee 

concerned 

A BILL 

To direct the Secretary of Labor to issue an occupational 

safety and health standard that requires employers to 

keep opioid overdose reversal drugs onsite and develop 

and implement training plans to respond to drug overdose emergencies and to amend the Omnibus Crime Control and Safe Streets Act of 1968 to expand the grants 

authorized under the Comprehensive Opioid Abuse Grant 

Program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 6243 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Overdose Reversal 

3 Medication Act’’ or the ‘‘ORM Act’’. 

4 SEC. 2. OPIOID OVERDOSE REVERSAL DRUG STANDARD. 

5 (a) INTERIM FINAL STANDARD.— 

6 (1) IN GENERAL.—Not later than 1 year after 

7 the date of enactment of this Act, the Secretary of 

8 Labor shall issue an interim final standard on work9 place availability of an opioid overdose reversal drug 

10 or device— 

11 (A) to require all employers to possess an 

12 opioid overdose reversal drug or device on site, 

13 where the required number of doses of such 

14 drug or device required is determined on the 

15 basis of the number of employees of the em16 ployer on site, type of occupation, and an as17 sessment of potential use; 

18 (B) that establishes guidelines for training 

19 on— 

20 (i) identifying signs and symptoms in21 dicating that usage of an opioid overdose 

22 drug or device is necessary; and 

23 (ii) how to administer such opioid 

24 overdose reversal drug or device; and 

25 (C) that provides for a period as deter26 mined appropriate by the Secretary, not to exVerDate Sep 11 2014 22:48 Nov 13, 2023 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H6243.IH H6243

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 6243 IH

1 ceed 1 year, during which the Secretary shall 

2 prioritize technical assistance and advice con3 sistent with section 21(d) of the Occupational 

4 Safety and Health Act of 1970 (29 U.S.C. 

5 670(d)) to employers subject to the standard 

6 with respect to compliance with the standard. 

7 (2) EFFECTIVE DATE OF INTERIM STAND8 ARD.—The interim final standard shall— 

9 (A) take effect on a date that is not later 

10 than 30 days after issuance; 

11 (B) shall have the same legal effect as an 

12 occupational safety and health standard as de13 fined by section 3 of the Occupational Safety 

14 and Health Act of 1970 (29 U.S.C. 652); and 

15 (C) be in effect until the final standard de16 scribed in subsection (b) becomes effective and 

17 enforceable. 

18 (3) FAILURE TO PROMULGATE.—If an interim 

19 final standard described in paragraph (1) is not 

20 issued by the date that is 1 year after the date of 

21 enactment of this Act, the provisions of this Act 

22 shall be in effect and enforced in the same manner 

23 and to the same extent as any standard promulgated 

24 under section 6(b) of the Occupational Safety and 

25 Health Act (29 U.S.C. 655(b)) until such provisions 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•HR 6243 IH

1 are superseded in whole by an interim final standard 

2 issued by the Secretary that meets the requirements 

3 of paragraph (1). 

4 (b) FINAL STANDARD.—Not later than 2 years after 

5 the date of enactment of this Act, the Secretary of Labor 

6 shall, pursuant to section 6 of the Occupational Safety and 

7 Health Act (29 U.S.C. 655), promulgate a final standard 

8 on workplace availability of opioid overdose reversal drugs 

9 or devices— 

10 (1) for the purposes described in subsection 

11 (a)(1)(A); 

12 (2) that shall include, at a minimum, require13 ments contained in the interim final standard pro14 mulgated under subsection (a); and 

15 (3) be effective and enforceable in the same 

16 manner and to the same extent as any standard pro17 mulgated under section 6(b) of the Occupational 

18 Safety and Health Act of 1970 (29 U.S.C. 655(b)). 

19 (c) DEFINITIONS.—In this section: 

20 (1) EMPLOYEE; EMPLOYER.—The terms ‘‘em21 ployee’’ and ‘‘employer’’ have the meaning given 

22 such terms in section 3 of the Occupational Safety 

23 and Health Act of 1970 (29 U.S.C. 652). 

24 (2) OPIOID OVERDOSE REVERSAL DRUG OR DE25 VICE.—The term ‘‘opioid overdose reversal drug or 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•HR 6243 IH

1 device’’ means an opioid overdose reversal drug or 

2 device approved, licensed, cleared, or otherwise au3 thorized for marketing by the Food and Drug Ad4 ministration. 

5 (3) SECRETARY.—The term ‘‘Secretary’’ means 

6 the Secretary of Labor. 

7 SEC. 3. EXPANSION OF THE COMPREHENSIVE OPIOID 

8 ABUSE GRANT PROGRAM. 

9 Section 3021 of title I of the Omnibus Crime Control 

10 and Safe Streets Act of 1968 (34 U.S.C. 10701(a)) is 

11 amended— 

12 (1) in subsection (a), by adding at the end the 

13 following: 

14 ‘‘(11) Developing, implementing, or expanding a 

15 program (which may include demonstration projects) 

16 that— 

17 ‘‘(A) provides training on carrying and ad18 ministering an opioid overdose reversal drug or 

19 device approved, licensed, cleared, or otherwise 

20 authorized for marketing by the Food and Drug 

21 Administration for local businesses, individuals, 

22 or other community entities that are likely to 

23 encounter individuals with substance use dis24 orders, but are not eligible for other Federal 

25 grant programs or to receive training or reVerDate Sep 11 2014 22:48 Nov 13, 2023 Jkt 049200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H6243.IH H6243

kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•HR 6243 IH

1 sources under such a grant program related to 

2 substance use prevention and treatment; or 

3 ‘‘(B) provides resources for employers, in4 dividuals, or community entities described in 

5 subparagraph (A) who have received training 

6 described in subparagraph (A) to acquire, 

7 carry, and administer such a drug or device.’’; 

8 and 

9 (2) by adding at the end the following: 

10 ‘‘(g) PREFERENTIAL CONSIDERATION.—In awarding 

11 grants under this part, the Attorney General may give 

12 preferential consideration to an application from an appli13 cant in a State that has in effect a law that exempts from 

14 criminal and civil liability individuals who carry or admin15 ister in good faith an opioid overdose reversal drug or de16 vice approved, licensed, cleared, or otherwise authorized 

17 for marketing by the Food and Drug Administration, if 

18 such an individual has been trained to carry or administer 

19 such drug or device.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB